PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration.

Abstract The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of ranibizumab (Lucentis; Genentech, South San Francisco, CA) and to determine potential predictors for early response.
PMID
Related Publications

Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration.

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Implementation studies of ranibizumab for neovascular age-related macular degeneration.

Authors

Mayor MeshTerms
Keywords
Journal Title ophthalmic surgery, lasers & imaging retina
Publication Year Start




PMID- 28419398
OWN - NLM
STAT- In-Process
DA  - 20170418
LR  - 20170418
IS  - 2325-8179 (Electronic)
IS  - 2325-8160 (Linking)
VI  - 48
IP  - 4
DP  - 2017 Apr 01
TI  - Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict
      Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular
      Degeneration.
PG  - 326-332
LID - 10.3928/23258160-20170329-07 [doi]
AB  - BACKGROUND AND OBJECTIVES: The aim of this study was to identify the rate of
      early visual acuity poor responders in patients with neovascular age-related
      macular degeneration (AMD) after the first intravitreal injection of ranibizumab 
      (Lucentis; Genentech, South San Francisco, CA) and to determine potential
      predictors for early response. PATIENTS AND METHODS: Patients with choroidal
      neovascularization secondary to AMD were evaluated before and 1 month after their
      first ranibizumab treatment. Early poor responders were defined as eyes gaining
      less than five letters 1 month after the first injection. RESULTS: Following the 
      first ranibizumab injection, 58% of 84 patients gained five or more letters.
      Beyond 42% poor responders, 31% displayed foveal retinal pigment epithelium (RPE)
      atrophy and 89% a loss of the external limiting membrane (ELM) integrity at
      baseline. However, the amount of intra- and subretinal fluid, pigment epithelial 
      detachment (PED), and subfoveal fibrosis showed a similar distribution between
      gainers and poor responders. CONCLUSION: Early poor responders present with more 
      RPE atrophy, as well as a loss of the ELM integrity at baseline optical coherence
      tomography. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:326-332.].
CI  - Copyright 2017, SLACK Incorporated.
FAU - Zandi, Souska
AU  - Zandi S
FAU - Weisskopf, Florian
AU  - Weisskopf F
FAU - Garweg, Justus G
AU  - Garweg JG
FAU - Pfister, Isabel B
AU  - Pfister IB
FAU - Pruente, Christian
AU  - Pruente C
FAU - Sutter, Florian
AU  - Sutter F
FAU - Hatz, Katja
AU  - Hatz K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ophthalmic Surg Lasers Imaging Retina
JT  - Ophthalmic surgery, lasers & imaging retina
JID - 101599215
EDAT- 2017/04/19 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/19 06:00
PHST- 2016/10/07 [received]
PHST- 2017/02/21 [accepted]
AID - 10.3928/23258160-20170329-07 [doi]
PST - ppublish
SO  - Ophthalmic Surg Lasers Imaging Retina. 2017 Apr 1;48(4):326-332. doi:
      10.3928/23258160-20170329-07.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>